Q-omics provides the consensus-scored MYL6P3 profile across patient tissues and cancer cell-line models. MYL6P3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYL6P3 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, MYL6P3 RNA expression shows 9,628 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight KIRC, STAD, and READ as cancer lineages where MYL6P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL6P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL6P3 survival associations across molecular data types. MYL6P3 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL6P3 RNA expression–survival associations across cancer types. High MYL6P3 expression shows unfavorable associations in ACC, CHOL, KICH and LUSC, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYL6P3 RNA expression.
This table summarizes MYL6P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MYL6P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL6P3 shows lower tumor expression in STAD, LUSC and PRAD and higher tumor expression in COAD. The STAD box plot shows higher MYL6P3 RNA expression in normal versus tumor tissue (log2 FC = −0.783, t-test p = .003).
This table shows molecular features associated with MYL6P3 in patient tissues and cancer cell lines. In patient samples, MYL6P3 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
